Tolmar, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$8.5M
Doctors Paid
9,082
Transactions
24,484
2024 Total
$2.5M
Payment Breakdown by Category
Research$7.8M (91.1%)
Food & Beverage$410,547 (4.8%)
Consulting$58,568 (0.7%)
Travel$13,078 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.8M | 2,872 | 91.1% |
| Food and Beverage | $410,547 | 20,366 | 4.8% |
| Honoraria | $241,518 | 115 | 2.8% |
| Consulting Fee | $58,568 | 24 | 0.7% |
| Space rental or facility fees (teaching hospital only) | $25,500 | 3 | 0.3% |
| Travel and Lodging | $13,078 | 20 | 0.2% |
| Education | $7,637 | 1,084 | 0.1% |
Payments by Type
Research
$7.8M
2,872 transactions
General
$756,847
21,612 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| TOL3010B | $1.9M | 0 | 381 |
| TOL2506A | $1.6M | 5 | 662 |
| Talconex (TOLMAR Calcipotriene Hydrate and Betamthason Dipropionate Topical Suspension 0.005%/0.064%) in the treatment of Scalp Psoriasis | $1.4M | 0 | 241 |
| A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | $873,387 | 0 | 1,065 |
| A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO for 12 Months | $529,422 | 0 | 131 |
| Open-label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study | $505,584 | 0 | 162 |
| TOL2581A | $170,193 | 3 | 31 |
| A Phase 3, Single Arm, OpenLabel Study Evaluating Ovarian Suppression Following ThreeMonth Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with HormoneReceptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)Negative Breast Cancer | $164,323 | 0 | 88 |
| TOL2707A | $150,335 | 0 | 5 |
| TOL2708C | $118,140 | 0 | 20 |
| A Pivotal Pharmacokinetic Bioequivalence Study Comparing Genericto Reference Liposome-Encapsulated Doxorubicin Hydrochloride inSubjects with Epithelial Ovarian Carcinoma Who Have FailedPlatinum-Based Chemotherapy | $115,045 | 0 | 14 |
| TOL2581A-CPP | $100,953 | 3 | 35 |
| TOL2506A-EXT | $67,270 | 0 | 25 |
| TOL2649G | $67,179 | 0 | 9 |
| Calcipotriene Ointment, 0.005% and Plaque Psoriasis | $12,450 | 0 | 1 |
| A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-ReceptorPositive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | $8,426 | 1 | 2 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Mrs. Kristin Sabanosh, Rn Msn Cpnp, RN MSN CPNP | Pediatrics | Morristown, NJ | $2,427 | $0 |
| Dr. David Morris, Md, MD | Student in an Organized Health Care Education/Training Program | Hendersonville, TN | $1,979 | $0 |
| Dr. Andrew Lee, M.d, M.D | Radiation Oncology | Irving, TX | $1,875 | $0 |
| Michael Zelefsky, Md, MD | Radiation Oncology | New York, NY | $1,800 | $0 |
| Cora Sternberg, Md, MD | Medical Oncology | New York, NY | $1,800 | $0 |
| Scott Tagawa, Md, MD | Hematology & Oncology | New York, NY | $1,800 | $0 |
| Dr. Adam Kibel, Md, MD | Urology | Boston, MA | $1,800 | $0 |
| Dr. Alicia Morgans, Md, MD | Medical Oncology | Boston, MA | $1,800 | $0 |
| Alan Bryce, M.d, M.D | Hematology & Oncology | Scottsdale, AZ | $1,800 | $0 |
| Jason Hafron, Md, MD | Urology | West Bloomfield, MI | $1,699 | $0 |
| Jill Samis, Md, MD | Pediatrics | Chicago, IL | $1,358 | $0 |
| Robert Hauser, Md, MD | Neurology | Tampa, FL | $1,200 | $0 |
| Ms. Keisha Bird, Arnp, ARNP | Nurse Practitioner | Jacksonville, FL | $1,016 | $0 |
| Abraham Morgentaler, M.d, M.D | Urology | Chestnut Hill, MA | $1,000 | $0 |
| Dr. Patrick Scannon, Md, MD | Internal Medicine | San Francisco, CA | $970.82 | $0 |
| Hannah Linden | Medical Oncology | Seattle, WA | $960.00 | $0 |
| David Allen, Md, MD | Pediatric Endocrinology | Madison, WI | $959.83 | $0 |
| Bruce Boston, Md, MD | Pediatric Endocrinology | Portland, OR | $953.32 | $0 |
| Dr. Javier Aisenberg, M.d, M.D | Pediatric Endocrinology | Hackensack, NJ | $950.00 | $0 |
| Dr. Cem Demirci, M.d, M.D | Pediatric Endocrinology | Hartford, CT | $950.00 | $0 |
| Marius Stan, M.d, M.D | Endocrinology, Diabetes & Metabolism | Rochester, MN | $850.00 | $0 |
| Peter Veneziano, Pa-C, PA-C | Physician Assistant | Chestnut Hill, MA | $801.10 | $0 |
| Dr. Daniel Petrylak, M.d, M.D | Hematology & Oncology | New Haven, CT | $790.00 | $0 |
| Nora Kurbaj, Pa-C, PA-C | Physician Assistant | Beverly, MA | $683.84 | $0 |
| Daniel Flynn, Md, MD | Pediatric Endocrinology | Boise, ID | $673.84 | $0 |
Ad
Top Products
- Leuprolide Acetate $1.7M
- Talconex (TOLMAR Calcipotriene Hydrate and Betamthason Dipropionate Topical Suspension 0.005%/0.064% $1.4M
Associated Products (13)
- Leuprolide Acetate $1.7M
- Talconex (TOLMAR Calcipotriene Hydrate and Betamthason Dipropionate Topical Suspension 0.005%/0.064% $1.4M
- JATENZO $1.2M
- TOL3010B $1.0M
- Paliperidone Palmitate $876,180
- TOL2707A $150,335
- TOL2581A $119,766
- Doxorubicin Hydrochloride Liposome Injection- Epithelial Ovarian Carcinoma $115,045
- TOL2708C $111,095
- Eligard 45mg and CPP $100,953
- TOL2649G $67,179
- Eligard $54,537
- Calcipotriene Ointment, 0.005% and Plaque Psoriasis $12,450
Payment Categories
- Food & Beverage $410,547
- Consulting $58,568
- Travel & Lodging $13,078
- Research $7.8M
About Tolmar, Inc.
Tolmar, Inc. has made $8.5M in payments to 9,082 healthcare providers, recorded across 24,484 transactions in the CMS Open Payments database. In 2024, the company paid $2.5M. The top product by payment volume is Leuprolide Acetate ($1.7M).
Payments were distributed across 146 medical specialties. The top specialty by payment amount is Hematology & Oncology ($209,143 to 153 doctors).
Payment categories include: Food & Beverage ($410,547), Consulting ($58,568), Research ($7.8M), Travel & Lodging ($13,078).
Tolmar, Inc. is associated with 13 products in the CMS Open Payments database, including Leuprolide Acetate, Talconex (TOLMAR Calcipotriene Hydrate and Betamthason Dipropionate Topical Suspension 0.005%/0.064%, and JATENZO.